IBMX

• Description:

  IBMX is a broad-spectrum phosphodiesterase (PDE) inhibitor, with IC50s of 6.5, 26.3 and 31.7 μM for PDE3, PDE4 and PDE5, respectively.

• Product Name Alternative:

  3-Isobutyl-1-methylxanthine; Isobutylmethylxanthine

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/IBMX.html

• Purity:

  99.99

• Solubility:

  DMSO : 125 mg/mL (ultrasonic) |Ethanol : ≥ 7.14 mg/mL

• Smiles:

  O=C(N1C)N(CC(C)C)C2=C(N=CN2)C1=O

• Molecular Formula:

  C10H14N4O2

• Molecular Weight:

  222.25

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Wu BN, et al. KMUP-1, a xanthine derivative, induces relaxation of guinea-pig isolated trachea: the role of the epithelium, cyclic nucleotides and K+ channels. Br J Pharmacol. 2004 Aug;142 (7) :1105-14|[2]Wei Y, et al. Angiotensin II type 2 receptor regulates ROMK-like K+ channel activity in the renal cortical collecting duct during high dietary K+ adaptation. Am J Physiol Renal Physiol. 2014 Oct 1;307 (7) :F833-43|[3]Hosseini A, et al. Differential metabolic effects of novel cilostamide analogs, methyl carbostiryl derivatives, on mouse and hyperglycemic rat. Iran J Basic Med Sci. 2012 Jul;15 (4) :916-25.|[4]Crosswhite P, et al. Inhibition of phosphodiesterase-1 attenuates cold-induced pulmonary hypertension. Hypertension. 2013 Mar;61 (3) :585-92.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  PDE3; PDE4

• CAS Number:

  [28822-58-4]